CRONOS GROUP INC (CRON.CA) Stock Fundamental Analysis
Canada - Toronto Stock Exchange - TSX:CRON - CA22717L1013 - Common Stock
3.35 CAD
+0.09 (+2.76%)
Taking everything into account, CRON scores 5 out of 10 in our fundamental rating. CRON was compared to 32 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for CRON as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, CRON is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
CRON had positive earnings in the past year.
In the past year CRON had a positive cash flow from operations.
CRON had negative earnings in 4 of the past 5 years.
CRON had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
CRON's Return On Assets of 3.06% is amongst the best of the industry. CRON outperforms 84.38% of its industry peers.
The Return On Equity of CRON (3.33%) is better than 84.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.06% | ||
| ROE | 3.33% | ||
| ROIC | N/A |
ROA(3y)-5.62%
ROA(5y)-9.8%
ROE(3y)-5.87%
ROE(5y)-10.3%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CRON has a better Profit Margin (27.27%) than 96.88% of its industry peers.
CRON's Profit Margin has declined in the last couple of years.
CRON has a Gross Margin (43.35%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 27.27% | ||
| GM | 43.35% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-62.81%
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CRON does not have a ROIC to compare to the WACC, probably because it is not profitable.
CRON has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CRON has been increased compared to 5 years ago.
CRON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 7.19 indicates that CRON is not in any danger for bankruptcy at the moment.
CRON's Altman-Z score of 7.19 is amongst the best of the industry. CRON outperforms 96.88% of its industry peers.
CRON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 7.19 |
ROIC/WACCN/A
WACC7.96%
2.3 Liquidity
CRON has a Current Ratio of 22.45. This indicates that CRON is financially healthy and has no problem in meeting its short term obligations.
CRON's Current ratio of 22.45 is amongst the best of the industry. CRON outperforms 100.00% of its industry peers.
CRON has a Quick Ratio of 21.28. This indicates that CRON is financially healthy and has no problem in meeting its short term obligations.
CRON has a better Quick ratio (21.28) than 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 22.45 | ||
| Quick Ratio | 21.28 |
3. Growth
3.1 Past
CRON shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 283.33%, which is quite impressive.
CRON shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -50.78% yearly.
CRON shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.00%.
Measured over the past years, CRON shows a very strong growth in Revenue. The Revenue has been growing by 37.71% on average per year.
EPS 1Y (TTM)283.33%
EPS 3YN/A
EPS 5Y-50.78%
EPS Q2Q%300%
Revenue 1Y (TTM)19%
Revenue growth 3Y16.47%
Revenue growth 5Y37.71%
Sales Q2Q%6.06%
3.2 Future
CRON is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -21.14% yearly.
Based on estimates for the next years, CRON will show a small growth in Revenue. The Revenue will grow by 7.39% on average per year.
EPS Next Y-115.3%
EPS Next 2Y-15.5%
EPS Next 3Y3.91%
EPS Next 5Y-21.14%
Revenue Next Year12.95%
Revenue Next 2Y21.44%
Revenue Next 3Y7.49%
Revenue Next 5Y7.39%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 22.33, which indicates a rather expensive current valuation of CRON.
Based on the Price/Earnings ratio, CRON is valued a bit cheaper than 78.13% of the companies in the same industry.
When comparing the Price/Earnings ratio of CRON to the average of the S&P500 Index (25.47), we can say CRON is valued inline with the index average.
A Price/Forward Earnings ratio of 33.31 indicates a quite expensive valuation of CRON.
Based on the Price/Forward Earnings ratio, CRON is valued a bit cheaper than the industry average as 68.75% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of CRON to the average of the S&P500 Index (34.42), we can say CRON is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.33 | ||
| Fwd PE | 33.31 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.5%
EPS Next 3Y3.91%
5. Dividend
5.1 Amount
CRON does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:CRON (11/21/2025, 7:00:00 PM)
3.35
+0.09 (+2.76%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners13.52%
Inst Owner ChangeN/A
Ins Owners6.24%
Ins Owner ChangeN/A
Market Cap1.28B
Revenue(TTM)132.36M
Net Income(TTM)36.10M
Analysts82.86
Price Target5.1 (52.24%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.4%
Min Revenue beat(2)-4.49%
Max Revenue beat(2)-0.31%
Revenue beat(4)0
Avg Revenue beat(4)-5%
Min Revenue beat(4)-14.99%
Max Revenue beat(4)-0.21%
Revenue beat(8)3
Avg Revenue beat(8)-1.43%
Revenue beat(12)4
Avg Revenue beat(12)-1.97%
Revenue beat(16)6
Avg Revenue beat(16)-3.29%
PT rev (1m)112.77%
PT rev (3m)112.77%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.33 | ||
| Fwd PE | 33.31 | ||
| P/S | 6.88 | ||
| P/FCF | N/A | ||
| P/OCF | 41.87 | ||
| P/B | 0.84 | ||
| P/tB | 0.9 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.15
EY4.48%
EPS(NY)0.1
Fwd EY3%
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)0.08
OCFY2.39%
SpS0.49
BVpS3.98
TBVpS3.71
PEG (NY)N/A
PEG (5Y)N/A
Graham Number3.67
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.06% | ||
| ROE | 3.33% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 27.27% | ||
| GM | 43.35% | ||
| FCFM | N/A |
ROA(3y)-5.62%
ROA(5y)-9.8%
ROE(3y)-5.87%
ROE(5y)-10.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-62.81%
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.11
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 209.86% | ||
| Cap/Sales | 20.77% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 22.45 | ||
| Quick Ratio | 21.28 | ||
| Altman-Z | 7.19 |
F-Score6
WACC7.96%
ROIC/WACCN/A
Cap/Depr(3y)70.04%
Cap/Depr(5y)158.35%
Cap/Sales(3y)6.62%
Cap/Sales(5y)22.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)283.33%
EPS 3YN/A
EPS 5Y-50.78%
EPS Q2Q%300%
EPS Next Y-115.3%
EPS Next 2Y-15.5%
EPS Next 3Y3.91%
EPS Next 5Y-21.14%
Revenue 1Y (TTM)19%
Revenue growth 3Y16.47%
Revenue growth 5Y37.71%
Sales Q2Q%6.06%
Revenue Next Year12.95%
Revenue Next 2Y21.44%
Revenue Next 3Y7.49%
Revenue Next 5Y7.39%
EBIT growth 1Y70.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year124.35%
EBIT Next 3Y27.54%
EBIT Next 5Y9.95%
FCF growth 1Y93.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y125.89%
OCF growth 3YN/A
OCF growth 5YN/A
CRONOS GROUP INC / CRON.CA FAQ
What is the fundamental rating for CRON stock?
ChartMill assigns a fundamental rating of 5 / 10 to CRON.CA.
What is the valuation status for CRON stock?
ChartMill assigns a valuation rating of 2 / 10 to CRONOS GROUP INC (CRON.CA). This can be considered as Overvalued.
How profitable is CRONOS GROUP INC (CRON.CA) stock?
CRONOS GROUP INC (CRON.CA) has a profitability rating of 3 / 10.
What is the expected EPS growth for CRONOS GROUP INC (CRON.CA) stock?
The Earnings per Share (EPS) of CRONOS GROUP INC (CRON.CA) is expected to decline by -115.3% in the next year.